Multidisciplinary Team Management of Lenvatinib Therapy in Differentiated Thyroid Cancer: Real-World Long-Term Treatment Outcomes
Balkan ORL-HNS · 20.07.2026 · 3 (1) · 1-10
DOI: 10.5152/bohns.2026.25133 ↗Kurz gefasst
Fachartikel in der Zeitschrift Balkan ORL-HNS, online erschienen am 20.07.2026. Verfasst von Takuya Demachi und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Lenvatinib demonstrates efficacy in radioiodine-refractory differentiated thyroid cancer (RR-DTC), but managing adverse events (AEs) remains challenging. This study evaluated real-world outcomes of lenvatinib therapy supervised by a multidisciplinary team without dedicated medical oncologists.
Methods
The study retrospectively analyzed 44 DTC patients treated with lenvatinib (June 2015–December 2023), divided into long-term (≥657 days, n = 22) and short-term (
Zitieren
APA
Demachi, T., Watanabe, A., Kimura, Y., Narumi, K., Fukui, N., Watanabe, Y., & Hirata, R. (2026). Multidisciplinary Team Management of Lenvatinib Therapy in Differentiated Thyroid Cancer: Real-World Long-Term Treatment Outcomes. Balkan ORL-HNS, 3(1), 1-10. https://doi.org/10.5152/bohns.2026.25133
Vancouver
Demachi T, Watanabe A, Kimura Y, Narumi K, Fukui N, Watanabe Y, et al. Multidisciplinary Team Management of Lenvatinib Therapy in Differentiated Thyroid Cancer: Real-World Long-Term Treatment Outcomes. Balkan ORL-HNS. 2026;3(1):1-10. doi:10.5152/bohns.2026.25133
BibTeX
@article{Demachi2026,
author = {Demachi, Takuya and Watanabe, Akihito and Kimura, Yuki and Narumi, Kao and Fukui, Nana and Watanabe, Yumi and Hirata, Riki},
title = {Multidisciplinary Team Management of Lenvatinib Therapy in Differentiated Thyroid Cancer: Real-World Long-Term Treatment Outcomes},
journal = {Balkan ORL-HNS},
year = {2026},
volume = {3},
number = {1},
pages = {1--10},
doi = {10.5152/bohns.2026.25133}
}
EUVIMED